Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
ARTV
Artiva Biotherapeutics, Inc.
AlloNK AB-101 is an allogeneic NK cell therapy platform, constituting Artiva's core product line.
|
$133.36M |
$5.50
+0.64%
|
|
GOSS
Gossamer Bio, Inc.
Inhaled seralutinib represents a drug-delivery platform that concentrates therapy in the lungs to treat pulmonary hypertension, a major differentiator.
|
$131.88M |
$0.52
-9.97%
|
|
CNTB
Connect Biopharma Holdings Limited
Lead asset CBP-201 (rademikibart) is a monoclonal antibody targeting IL-4Rα, directly fitting Monoclonal Antibody Therapeutics.
|
$131.50M |
$2.35
-0.42%
|
|
SPRO
Spero Therapeutics, Inc.
Tebipenem HBr is an oral small-molecule antibiotic, which is the lead product and central to Spero’s current business focus.
|
$130.56M |
$2.33
-0.64%
|
|
ABOS
Acumen Pharmaceuticals, Inc.
Sabirnetug is developed as an Alzheimer's disease therapeutic.
|
$129.63M |
$2.15
+9.69%
|
|
ACNT
Ascent Industries Co.
Custom manufacturing / contract manufacturing services.
|
$129.23M |
$13.40
-2.86%
|
|
CNFN
CFN Enterprises Inc.
CNFN's Ranco segment operates as a contract manufacturer/co-packer and white-label producer for clients.
|
$125.70M |
$1.06
|
|
TKNO
Alpha Teknova, Inc.
Teknova provides GMP-grade manufacturing for clinical-relevant reagents and custom solutions, aligning with contract manufacturing services.
|
$124.99M |
$2.21
-5.14%
|
|
ATRA
Atara Biotherapeutics, Inc.
Atara focuses on tab-cel (Ebvallo), an allogeneic T-cell therapy.
|
$123.46M |
$17.70
+0.71%
|
|
TNXP
Tonix Pharmaceuticals Holding Corp.
TNX-102 SL is Tonix's lead oral small-molecule drug for fibromyalgia (cyclobenzaprine HCl sublingual), a direct product the company develops and plans to bring to market.
|
$122.55M |
$13.75
-1.65%
|
|
BDSX
Biodesix, Inc.
Biodesix's Development Services revenue aligns with CRO-like outsourced diagnostic testing for partners.
|
$121.72M |
$15.62
+2.06%
|
|
SGMO
Sangamo Therapeutics, Inc.
Core platform enabling genomic medicine via gene therapy and genome regulation (ZF/ZFR) technology.
|
$119.24M |
$0.38
-3.82%
|
|
ALXO
ALX Oncology Holdings Inc.
ALX Oncology explicitly focuses on cancer therapies (immuno-oncology), placing it under Biotech - Oncology.
|
$117.28M |
$2.13
-2.51%
|
|
FATE
Fate Therapeutics, Inc.
Fate develops oncology-focused immunotherapies, aligning with Biotech - Oncology.
|
$116.48M |
$1.01
|
|
VTVT
vTv Therapeutics Inc.
Cadisegliatin is an oral, small-molecule therapeutic developed by the company for Type 1 Diabetes, directly matching the 'Oral Small Molecule Therapeutics' category.
|
$115.00M |
$37.30
+3.61%
|
|
KRRO
Korro Bio, Inc.
KRRO's core offering is its OPERA oligonucleotide platform enabling RNA editing therapeutics (oligonucleotide-based editing).
|
$113.91M |
$12.18
+0.66%
|
|
RPTX
Repare Therapeutics Inc.
Core company focus is oncology therapeutics with a synthetic lethality approach (Biotech - Oncology).
|
$113.84M |
$2.65
-0.19%
|
|
IPSC
Century Therapeutics, Inc.
Directly develops iPSC-derived cell therapies (CAR-iT, CAR-iNK, Allo-Evasion-enabled products) and related platforms.
|
$112.31M |
$1.76
+35.38%
|
|
MGNX
MacroGenics, Inc.
Company develops bispecific antibody therapies via its DART platform, including lorigerlimab.
|
$108.71M |
$1.72
|
|
UNCY
Unicycive Therapeutics, Inc.
Lead programs Oxylanthanum Carbonate (OLC) and UNI-494 are oral small-molecule therapeutics targeting kidney disease and hyperphosphatemia/acute kidney injury.
|
$106.15M |
$6.21
+3.41%
|
|
ACOG
Alpha Cognition Inc. Common Stock
ZUNVEYL is Alpha Cognition's lead therapeutic targeting Alzheimer's disease.
|
$105.05M |
$6.50
+5.18%
|
|
HLVX
HilleVax, Inc.
Direct vaccine development activity with norovirus vaccine candidates (HIL-216.00) and existing vaccine focus.
|
$104.79M |
$2.09
|
|
GUTS
Fractyl Health, Inc. Common Stock
Rejuva gene therapy platform (RJVA-001) and related candidates (RJVA-002) classify as Biotech - Gene Therapy, a core product line aimed at durable disease modification.
|
$103.60M |
$2.02
-2.18%
|
|
CRBP
Corbus Pharmaceuticals Holdings, Inc.
Corbus's pipeline is focused on oncology assets (CRB-701 and CRB-601) representing biotech oncology products.
|
$103.19M |
$8.02
-4.75%
|
|
AGEN
Agenus Inc.
Agenus' core focus is oncology with immunotherapy approaches (BOT/BAL) in MSS CRC, supporting Biotech - Oncology.
|
$101.97M |
$2.92
-8.59%
|
|
GNLX
Genelux Corporation
Genelux focuses on oncology-focused viral immunotherapies, categorized under Biotech - Oncology.
|
$101.23M |
$2.69
+0.19%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RaniPill is the core drug-delivery platform enabling oral administration of biologics, central to the company's offering.
|
$97.74M |
$1.35
-0.74%
|
|
CDXS
Codexis, Inc.
Codexis is pivoting to manufacturing RNAi therapeutics using the ECO Synthesis platform, directly targeting RNAi drug production.
|
$97.49M |
$1.25
+15.74%
|
|
XTNT
Xtant Medical Holdings, Inc.
Xtant operates as an OEM/contract manufacturer for orthobiologic and implant products.
|
$97.35M |
$0.73
-6.45%
|
|
ONCY
Oncolytics Biotech Inc.
Pelareorep is an oncolytic virus immunotherapy developed by Oncolytics Biotech, placing the company in Biotech - Oncology.
|
$96.46M |
$1.05
-0.94%
|
|
ANIX
Anixa Biosciences, Inc.
CER-T CAR-T therapy is a direct cell therapy product focused on oncology.
|
$95.79M |
$2.90
-0.34%
|
|
TNYA
Tenaya Therapeutics, Inc.
Tenaya's lead programs TN-201 and TN-401 are gene therapies (AAV-based) targeting genetic heart diseases.
|
$94.75M |
$0.82
+40.73%
|
|
ATYR
aTyr Pharma, Inc.
Efzofitimod is a biologic immunomodulator addressing inflammation in ILD, aligning with Immunology Therapeutics.
|
$94.06M |
$0.96
-3.19%
|
|
PYXS
Pyxis Oncology, Inc.
Pyxis Oncology is a biotechnology company focused on oncology therapeutics, with MICVO as its lead asset in cancer.
|
$92.41M |
$1.35
-9.40%
|
Showing page 16 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
